Cargando…

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

Detalles Bibliográficos
Autores principales:	Cummings, Jeffrey, Aisen, Paul, Lemere, Cynthia, Atri, Alireza, Sabbagh, Marwan, Salloway, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111757/ https://www.ncbi.nlm.nih.gov/pubmed/33971962 http://dx.doi.org/10.1186/s13195-021-00838-z

Ejemplares similares

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
por: Assunção, Sheila Seleri, et al.
Publicado: (2022)

Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019”
por: Sabbagh, Marwan Noel, et al.
Publicado: (2020)

TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
por: Salloway, Stephen, et al.
Publicado: (2023)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
por: Tolar, Martin, et al.
Publicado: (2020)

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
por: Salloway, Stephen, et al.
Publicado: (2021)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
por: Arndt, Joseph W., et al.
Publicado: (2018)

Quantifying exposure to running for meaningful insights into running-related injuries
por: Davis IV, John J, et al.
Publicado: (2019)

Ethical, strategic and meaningful involvement of women living with HIV starts at the beginning
por: Namiba, Angelina, et al.
Publicado: (2016)

How Will Aducanumab Approval Impact AD Research?
por: Weiner, Michael W., et al.
Publicado: (2021)

Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
por: Silvestro, Serena, et al.
Publicado: (2022)

Infrequent false positive [(18)F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
por: Ikonomovic, Milos D., et al.
Publicado: (2018)

Putting Meaning into Meaningful Use: A Roadmap to Successful Integration of Evidence at the Point of Care
por: McGinn, Thomas
Publicado: (2016)

Collaborative Challenges of Multi-Cohort Projects in Pharmacogenetics—Why Time Is Essential for Meaningful Collaborations
por: Franchini, Filippo, et al.
Publicado: (2022)

Using the Delphi method to identify meaningful and feasible outcomes for pharmaceutical value-based contracting
por: Swart, Elizabeth C S, et al.
Publicado: (2020)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

Health Information Technology: Meaningful Use and Next Steps to Improving Electronic Facilitation of Medication Adherence
por: Bosworth, Hayden B, et al.
Publicado: (2016)

Unintended Consequences of Nationwide Electronic Health Record Adoption: Challenges and Opportunities in the Post-Meaningful Use Era
por: Colicchio, Tiago K, et al.
Publicado: (2019)

Seeking Meaningful Innovation: Lessons Learned Developing, Evaluating, and Implementing the Electronic Patient-Reported Outcome Tool
por: Steele Gray, Carolyn
Publicado: (2020)

Matching researchers’ needs and patients’ contributions: practical tips for meaningful patient engagement from the field of rheumatology
por: Schoemaker, Casper G, et al.
Publicado: (2023)

Is the Concept of Solastalgia Meaningful to Pacific Communities Experiencing Mental Health Distress Due to Climate Change? An Initial Exploration
por: Tupou, Trish, et al.
Publicado: (2023)

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
por: Lin, Lin, et al.
Publicado: (2022)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: Open peer commentary
por: Cummings, Jeffrey
Publicado: (2023)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Critical Appraisal of Amyloid Lowering Agents in AD
por: Decourt, Boris, et al.
Publicado: (2021)

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
por: Bateman, Randall J, et al.
Publicado: (2011)

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2020)

Alzheimer’s disease: amyloid-based pathogenesis and potential therapies
por: Zhou, Yixiu, et al.
Publicado: (2018)

Spaceship Earth Revisited: The Co-Benefits of Overcoming Biological Extinction of Experience at the Level of Person, Place and Planet
por: Prescott, Susan L., et al.
Publicado: (2020)

The role of animal models in advancing amyloid-beta immunotherapy to the clinic
por: Games, Dora, et al.
Publicado: (2010)

Management of Amyloid Cardiomyopathy in Resource-Constrained Settings: Challenges and Opportunities
por: Singh, Suvir, et al.
Publicado: (2021)

Topical Insights Into the Post-Approval Controversies of Aducanumab
por: Kumar, Dhiraj, et al.
Publicado: (2021)

Re: Aducanumab-Related ARIA: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2vas1udeulg7keevs4ihot77b5